Growing up as the daughter of two physicians in Budapest, Hungary, Emese Zsiros, MD, PhD, FACOG, recognized her passion for medicine at an early age. She earned a combined MD/PhD at one of the top medical schools in Europe before heading to the United States to complete her OB/GYN residency.
Ovarian Cancer
Women with a strong family history of breast and ovarian cancer have an increased risk of developing these diseases. Sometimes this strong family history indicates a BRCA1 or BRCA2 gene mutation, making the odds of developing these cancers even higher.
The U.S. Supreme Court's unanimous ruling — that companies may no longer patent human genes — resonated across the cancer community, resulting in promising news for cancer patients and researchers.
Ovarian cancer is often called the “silent killer” because there is a general lack of awareness of the symptoms of the disease, which are nonspecific and may be confused with less serious gastrointestinal conditions.
Borderline ovarian tumors represent a small subset of epithelial ovarian tumors. Because it’s an uncommon and unfamiliar diagnosis, it’s often misunderstood.
By studying the effects of bevacizumab (brand name AvastinTM), a drug currently FDA-approved for use in the treatment of several other cancers, a research team led by the Gynecologic Oncology Group (GOG) has laid the groundwork for a possible new